Cargando…

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer

Detalles Bibliográficos
Autores principales:	Nemunaitis, John, Bedell, Cynthia, Klucher, Kevin, Vo, Alex, Whiting, Sam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990302/ http://dx.doi.org/10.1186/2051-1426-1-S1-P240

Ejemplares similares

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality
por: Wheeler, Graham
Publicado: (2013)

Addressing the barriers to implementing model based designs in dose escalation studies
por: Cornelius, Victoria, et al.
Publicado: (2015)

Some small sample properties of the EWOC design in dose escalation trials
por: Kinnersley, Nelson
Publicado: (2015)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2006)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
por: Tung, F, et al.
Publicado: (2012)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2006)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2008)

A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer
por: Cohen, Roger B, et al.
Publicado: (2014)

Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models
por: De Meyer, Micaël, et al.
Publicado: (2013)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
por: Pegram, Mark D, et al.
Publicado: (2009)

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
por: Kefford, Richard, et al.
Publicado: (2014)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

De-escalation therapy: 1-year experience in a general intensive care unit
por: Gyurov, E, et al.
Publicado: (2005)

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham, et al.
Publicado: (2015)

P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS
por: Ali, H., et al.
Publicado: (2022)

Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response
por: Zizzari, Ilaria G, et al.
Publicado: (2013)

Neoadjuvant stereotactic radiosurgery for intracerebral metastases of solid tumors (NepoMUC): a phase I dose escalation trial
por: Diehl, Christian D., et al.
Publicado: (2019)

Elles ont aimé /
por: Benzoni, Juliette
Publicado: (2002)

P1535: SAFETY AND TOLERABILITY OF SINGLE ESCALATING DOSES OF INTRAVENOUS NIPOCALIMAB IN HEALTHY JAPANESE ADULTS: A RANDOMIZED, PHASE 1 PLACEBO-CONTROLLED STUDY
por: Leu, J., et al.
Publicado: (2022)

De-escalation practice pattern in an Indian intensive care unit
por: Bhakta, A, et al.
Publicado: (2010)

A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
por: Urba, Walter, et al.
Publicado: (2015)

Antibiotic costs in bacteremic and nonbacteremic patients treated with the de-escalation approach
por: Evodia, E, et al.
Publicado: (2008)

De-escalation of empiric antibiotic therapy in sepsis - an indian observational study
por: Jakkinaboina, S, et al.
Publicado: (2015)

Les Dieux ont soif /
por: France, Anatole, 1844-1924
Publicado: (1967)

A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma
por: Hurwitz, Herbert, et al.
Publicado: (2014)

A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
por: Baughman, Jan, et al.
Publicado: (2015)

P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE
por: Wang, M., et al.
Publicado: (2022)

De-escalation of antimicrobial therapy in Gram-negative sepsis: easier said than done?
por: Phee, L, et al.
Publicado: (2011)

Forecasting escalation of cardio-respiratory instability using noninvasive vital sign monitoring data
por: Guillame-Bert, M, et al.
Publicado: (2015)

P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Atallah, Ehab, et al.
Publicado: (2023)

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
por: Nemunaitis, John J, et al.
Publicado: (2013)

A165 FCGBP IN THE COLON IS SPATIALLY DEPENDENT ON MUC2 EXPRESSION AND IS DEGRADED IN DEXTRAN SULFATE SODIUM-INDUCED COLITIS
por: Kim, A, et al.
Publicado: (2023)

Ils ont travaillé au CERN
Publicado: (1962)

CCNP ONT quick reference sheets.
por: Stewart, Brent, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_tv3ql21ej1jhg34152hu4tusu5